GlaxoSmithKline plc (GSK)

NYSE - NYSE Real Time Price. Currency in USD
43.42-0.16 (-0.37%)
At close: 4:02 PM EDT

43.03 -0.39 (-0.90%)
Pre-Market: 8:16 AM EDT

People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close43.58
Bid43.04 x 3400
Ask43.08 x 3800
Day's Range43.18 - 43.53
52wk Range37.24 - 45.58
1y Target EstN/A
Market Cap105.53B
P/E Ratio (ttm)2,713.75
Avg Vol (3m)2,981,738
Dividend & Yield2.20 (5.08%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • TheStreet.com2 days ago

    5 Stocks to Sell Now Before It's Too Late

    These stocks could be toxic to your portfolio in the month ahead.

  • Financial Times3 days ago

    [$$] GSK's 'fiercely competitive' Emma Walmsley faces test of experience

    To most people who have encountered Emma Walmsley, her appointment this week as the next head of GlaxoSmithKline, the UK drugmaker, will probably come as little surprise. "She's ruthlessly ambitious," ...

  • Reuters4 days ago

    Hard to swallow: emerging markets get tougher for drugmakers

    Emerging markets have lost their luster for Big Pharma making drug firms ever more dependent on the United States for growth just as American anger over high medicine prices is building. A few years ago, the developing world was seen as a savior as patent after patent expired across the United States and Europe, but emerging market sales growth at the top drug firms slowed to less than two percent in the latest quarter. Forecasts from independent experts IMS Health now suggest the United States will account for 55 percent of sales growth between 2016 and 2020, with emerging markets only contributing 30 percent.